Home›Trial›NCT07252232
🔬NCT07252232Phase 3RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Conditions
Pancreatic CancerPDACPDAC - Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma (PDAC)Resected Pancreatic Adenocarcinoma
Interventions / Drugs
daraxonrasib
View on ClinicalTrials.gov ↗
Sponsor
RVMD
Revolution Medicines
Precision Oncology
F35/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorRevolution Medicines, Inc.
Data Retrieved2026-04-11 04:26:28.070655+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.